NOXXON Pharma kündigt Zusammenarbeit mit Nationalem Zentrum für Tumorerkrankungen in Heidelberg bei NOX-A12/Keytruda® Phase 1/2 Kombinationsstudie anWeiterlesen...
NOXXON PHARMA secures a private placement of €1 million and additional financing of up to €10 million through convertible notes with share subscritpion warrants attached to finance further clinical development of NOX-A12Weiterlesen...
NOXXON PHARMA N.V. berichtet über Finanzergebnisse 2016 und informiert über fortgeschrittene Verhandlung über eine WandelanleiheWeiterlesen...
NOXXON Pharma announces experienced Industry Cancer Clinician Dr. Jarl Ulf Jungnelius to serve as NOXXON CMOWeiterlesen...
NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to AptarionWeiterlesen...
THESE DATA WILL BE PRESENTED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) CONFERENCE
Berlin, Germany, December 5, 2016, NOXXON Pharma N.V. (Alternext Paris: ALNOX) a clinical-stage biopharmaceutical company primarily focused on cancer treatment, announces that it presented data at the ASH conference in San Diego, California studying the role of CXCL12 inhibition by NOX-A12 (olaptesed pegol) on Natural Killer (NK) cells in tumor stroma spheroids, a preclinical model that mimics the complexity of the tumor microenvironment. These studies showed that NOX-A12 synergizes with NK cell mediated antibody-dependent cellular cytotoxicity (ADCC). Further studies of NOX-A12 with agents working through NK cell-based therapies are warranted.
CXCL12 Inhibition by NOX-A12 (Olaptesed Pegol) Synergizes With the ADCC Activity of CD20 Antibodies by Increasing NK Cell Infiltration in a 3D Lymphoma Model
Dirk Zboralski, Anna Kruschinski, Dirk Eulberg and Axel Vater
Location & time:
58th ASH Annual Meeting, San Diego, CA, USA, Abstract #3021, Session 625 Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster II. Sunday, December 4, 2016 from 18:00 – 20:00
The poster may be downloaded from the company’s website: http://www.noxxon.com/downloads/poster/ash2016.pdf
NOX-A12, which inhibits the key tumor microenvironment chemokine CXCL12, may be a key partner for a wide range of IO (immuno-oncology) agents. NOXXON has generated promising pre-clinical and clinical data, including recent animal data showing synergy with a checkpoint inhibitor as well as recent phase 2a trials in multiple myeloma and a second hematological cancer that showed a safety profile that supports further development and first signs of efficacy. The Company believes that additional clinical trials are warranted to investigate combinations of NOX-A12 multiple classes of IO agents including those acting on or through T-cells and NK cells.